Oriental Aromatics Ltd

- There are no specific mentions of any current or future fundraising through debt or equity in the provided transcript. - The company maintains financial discipline with a net debt-to-equity ratio of 0.45x as of December 31, 2024, indicating a stable financial position to support growth. - The management indicates focusing on operational efficiencies, strengthening product portfolios, and consolidations rather than new funding rounds. - Any updates about new capacities or plants will be shared if they arise, but currently, there is no indication of new fundraising plans. - For specific queries regarding revenue potential or expansion beyond current plans, investors are advised to reach out to Investor Relations for further disclosures.

- Currently, there are no new plans for additional capacity or new plants beyond the recently commissioned ones. (Page 9) - The recent expansions include the Mahad plant and the hydrogenation plant at Baroda, which are part of ongoing growth and consolidation efforts. (Pages 15-16) - The Mahad facility is recently commissioned and expected to reach about 40-50% utilization initially, ramping up substantially in coming quarters. (Page 10) - The hydrogenation plant is expected to achieve 60-70% utilization by end of FY 2025 and reach optimal levels by FY 2026. (Page 10) - The Mahad site is a large greenfield site with room for future expansions. (Page 16) - The company has not disclosed any new capex or strategic investment plans at this time and invites queries via their IR Managers for further details. (Page 9 and 19)

- The company is targeting a revenue milestone of Rs. 1,000 crores for the current financial year, with efforts ongoing to achieve this as early as possible, although it may extend to the next year depending on market conditions. - Volume growth is expected to be robust, with a 6% year-on-year increase already seen in the recent quarter. - Double-digit volume growth is anticipated for FY '26, driven by demand stability globally and new products launched from recently commissioned plants in Baroda and Mahad. - The Specialty Aroma Ingredients and Fragrance divisions are showing significant growth in both value and volume. - New products introduced have been accepted domestically and internationally, supporting optimistic sales volume projections. - Seasonal and macroeconomic factors cause some quarter-to-quarter fluctuations, but overall growth trajectory remains positive.

- The company aims to reach Rs. 1,000 crore revenue milestone soon, focusing on sustainable and profitable growth; crossing this line this financial year is possible but not guaranteed. - EBITDA margins are expected to normalize at 10% to 12% until plants reach optimal capacity. - New plants at Baroda and Mahad are ramping up; Mahad plant expected to break even around 60% capacity utilization, likely in the second half of next year. - Hydrogenation facility projected to reach 60-70% utilization by end of FY '25 and optimal capacity by FY '26. - Operating efficiencies, product mix optimization, and volume growth (potentially double-digit for FY '26) expected to drive profitability improvements. - Overall, EBITDA growth has been significant year-on-year (181% increase in nine months), net profit turned positive vs. loss previously, indicating robust forward momentum. - Management commits to long-term growth from 2018 to 2025 with steady margin improvement and operational scalability.

- The company is currently focusing on consolidating launched products rather than expanding new programs. - Significant contracts related to the new products, especially from the Mahad plant, are anticipated primarily in Q1 of the next financial year (FY 2026) when bidding for calendar year 2025 H2 contracts takes place. - Initial sales in Q4 will mainly be spot sales to customers. - The business model emphasizes generic products rather than patented ones, ensuring freedom to operate and supplier relationships with major innovation-driven companies. - No specific quantitative details on the current order book or pending orders were disclosed during the call. - Investors wanting more specific orderbook information were advised to contact the company's Investor Relations team at Valorem Advisors for detailed queries.